AstraZeneca reports Phase III results for Ultomiris and Sone-Ve

AstraZeneca has released findings from two Phase III studies, reporting outcomes for Ultomiris in thrombotic microangiopathy following HSCT-TMA and Sone-Ve in advanced gastric and GEJ cancers.

The post AstraZeneca reports Phase III results for Ultomiris and Sone-Ve appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.